Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVS459
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
EVS459 is a radioconjugate theranostic developed by Novartis Pharmaceuticals. It is a low molecular weight compound that targets the folate receptor alpha (FRα), which is overexpressed in various cancers. The drug consists of a folic acid-binding motif, a linker, and a DOTA chelator. It can be labeled with Lutetium-177 ([177Lu]Lu-EVS459) for therapeutic purposes and SPECT imaging, or with Gallium-68 ([68Ga]Ga-EVS459) for diagnostic PET imaging. It was being investigated for the treatment of advanced high-grade serous ovarian cancer and locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma.
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on EVS459.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVS459.